Cytodyn Inc (CYDY)

[gestalt2]

Nader say this is low risk AT THIS POINT because the trial for the combo HIV indication is done and the risk that there is a failure during the trial or not good trial results is gone. The hard part of getting through a p3 FDA trial is over. He also is making this statement because over 800 patients have been injected, some for many years, with no safety issues.

If you compare this company to some other biotech (all small biotechs are high risk) in the middle of any phase of clinical trials, those companies are facing the possiblity of a trial failure, Cytodyn does not have that concern AT THIS POINT.